DOCSLIB.ORG

Sous Forme De Sel De Calcium

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sous Forme De Sel De Calcium Nom molécule Abamectine Absinthe (teinture de) Acamprosate (sous forme de sel de calcium) Acarbose Acébutolol (sous forme de chlorhydrate) Acéclofénac Acéfylline heptaminol Acémétacine Acépromazine Acépromazine (sous forme de maléate) Acétate de calcium Acétate de magnésium (sous forme de tétrahydrate) Acétate de potassium Acétate de sodium Acétate de sodium (sous forme de trihydrate) Acétazolamide Acétylcholine (sous forme de chlorure) Acétylcystéine Acétylméthionine Acétylméthionine (sous forme de sel de magnésium) Achillée millefeuille Aciclovir Acide acétylsalicylique Acide acétylsalicylique (sous forme de carbasalate de calcium) Acide acétylsalicylique (sous forme de lysinate) Acide acétylsalicylique (sous forme de sel de sodium) Acide adipique Acide alendronique (sous forme de sel de sodium) Acide alginique Acide alginique (sous forme de sel de calcium) Acide aminocaproïque Acide ascorbique Acide ascorbique (sous forme de sel de calcium) Acide ascorbique (sous forme de sel de sodium) Acide aspartique Acide aspartique (sous forme de sel de calcium) Acide aspartique (sous forme de sel de magnésium) Acide aspartique (sous forme de sel de magnésium et de potassium) Acide aspartique (sous forme de sel de magnésium et de potassium dihydraté) Acide aspartique (sous forme de sel de magnésium tétrahydraté) Acide aspartique (sous forme de sel de potassium) Acide aspartique (sous forme de sel de potassium hémihydraté) Acide aspartique (sous forme de zinc) Acide benzoïque Acide benzoïque (sous forme de benzyle) Acide benzoïque (sous forme de sel de calcium) Acide benzoïque (sous forme de sel de potassium) Acide benzoïque (sous forme de sel de sodium) Acide borique Acide camsilique (sous forme de sel de sodium) Acide chénodésoxycholique Acide citrique Acide citrique (sous forme de monohydrate) Acide clavulanique Acide clavulanique (sous forme de sel de potassium) Acide clavulanique (sous forme de sel de potassium dilué) Acide clodronique Acide clodronique (sous forme de disodium tétrahydraté) Acide cromoglicique (sous forme de sel de disodium) Acide déoxyribonucléique Acide D-glucarique (sous forme de sel de calcium) Acide diglutamique (sous forme de sel de magnésium) Acide édétique Acide édétique (sous forme de sel de calcium) Acide édétique (sous forme de sel de sodium) Acide érythorbique Acide étacrynique Acide folinique (sous forme de sel de calcium) Acide folique Acide formique Acide formique (sous forme de sel de calcium) Acide formique (sous forme de sel de magnésium) Acide formique (sous forme de sel de sodium) Acide fumarique Acide fusidique (sous forme de diéthanolamine) Acide fusidique (sous forme de sel de sodium) Acide fusidique (sous forme d'hémihydrate) Acide gluconique Acide glucuronique (sous forme de bétaïne) Acide glucuronique (sous forme de diéthanolamine) Acide glucuronique (sous forme de sel de potassium) Acide glutamique Acide glutamique (sous forme d'ammonium) Acide glutamique (sous forme de sel de calcium tétrahydraté) Acide glutamique (sous forme de sel de magnésium tétrahydraté) Acide glutamique (sous forme de sel de potassium) Acide glutamique (sous forme de sel de sodium) Acide hyaluronique Acide hyaluronique (sous forme de sel de sodium) Acide iodique (sous forme de sel de calcium) Acide iodique (sous forme de sel de potassium) Acide iodique (sous forme de sel de sodium) Acide iopanoïque Acide iotalamique Acide ioxaglique Acide lactique Acide lactique (sous forme de sel de magnésium dihydraté) Acide lactique (sous forme de sel de potassium) Acide L-folinique (sous forme de sel de calcium pentahydraté) Acide maléique Acide malique Acide méclofénamique Acide méfénamique Acide métatartrique Acide nalidixique Acide nicotinique Acide nicotinique (sous de forme de benzylester) Acide nicotinique (sous forme de méthyle ester) Acide niflumique Acide oléique Acide orotique Acide orotique (sous forme de monohydrate) Acide orotique (sous forme de sel de magnésium) Acide orthophosphorique Acide oxalique Acide oxalique (sous forme de dihydrate) Acide oxolinique Acide oxolinique (sous forme de sel de sodium) Acide palmitique Acide pantothénique Acide pantothénique (sous forme de sel de calcium) Acide pantothénique (sous forme de sel de sodium) Acide peracétique Acide picrique Acide pipémidique (sous forme de trihydrate) Acide propionique (sous forme de sel de calcium) Acide propionique (sous forme de sel de sodium) Acide ranexamique Acide salicylique Acide salicylique (sous forme de méthyle ester) Acide salicylique (sous forme de sel de sodium) Acide salicylique (sous forme d'hydroxyéthyle) Acide S-lactique Acide sorbique Acide sorbique (sous forme de sel de calcium) Acide sorbique (sous forme de sel de potassium) Acide stéarique Acide succinique Acide sulfurique Acide tannique Acide tartrique Acide ténoïque Acide ténoïque (sous forme de sel de lithium) Acide thioctique Acide tiaprofénique Acide tiludronique (sous forme de sel de disodium) Acide tolfénamique Acide trichloracétique Acide undécylénique Acide 2-méthyl-2-phénoxypropionique (sous forme de sel de sodium) Acide 3-thénoïque (sous forme de sel de lithium) Acide 4-aminobenzoïque Acides gras polyinsaturés Acides gras sodés Acitrétine Adapalène Adénine Adénosine Adénosine (sous forme de diphosphate) Adénosine (sous forme de phosphate) Adénosine (sous forme de triphosphate) Afoxolaner Aglépristone Air médicinal Air médicinal reconstitué Alanine Alaréline Albendazole Albendazole (sous forme d'oxyde) Alcuronium (sous forme de chlorure) Alfacalcidol Alfaprostol Alfaxalone Alfentanil (sous forme de chlorhydrate) Alfuzosine (sous forme de chlorhydrate) Allantoïne Allopurinol Almagate Aloe vera extrait des feuilles entières Aloe vera gel Aloès (poudre de) Alpha-cyperméthrine Alpha-tocophérol Alpha-tocophérol (sous forme d'acétate) Alpha-tocophérol (sous forme d'hydrogénosuccinate) Alprazolam Alprénolol (sous forme de chlorhydrate) Alprostadil Altéplase pour solution injectable Altizide Altrénogest Aluminium Aluminium (sous forme d'acétotartrate) Aluminium (sous forme d'hydroxyacétate hydraté) Aluminium (sous forme stéarinée) Alun Alvérine (sous forme de citrate) Amantadine (sous forme de chlorhydrate) Ambroxol (sous forme de chlorhydrate) Amfétamine (sous forme de sulfate) Amidotrizoate de sodium Amidotrizoïque acide (sous forme de dihydrate) Amikacine Amikacine (sous forme de sulfate) Amiloride (sous forme de chlorhydrate) Aminoglutéthimide Aminophylline Aminophylline (sous forme hydratée) Aminosalicylate de sodium (sous forme dihydrate) Amiodarone (sous forme de chlorhydrate) Amisulpride Amitraz Amitriptyline (sous forme de chlorhydrate) Amlodipine (sous forme de bésilate) Amobarbital Amobarbital (sous forme de sel de sodium) Amoxicilline Amoxicilline (sous forme de sel de sodium) Amoxicilline (sous forme de trihydrate) Ampérozide (sous forme de chlorhydrate) Amphotéricine B Ampicilline Ampicilline (sous forme de sel de sodium) Ampicilline (sous forme de trihydrate) Amprolium Amprolium (sous forme de chlorhydrate) Amylase Amyléine (sous forme de chlorhydrate) Anétholtrithione Angelicae radix aetheroleum Anis (huile essentielle de) Antazoline (sous fome de chlorhydrate) Antimoine (sous forme d'antimoniate de méglumine) Antimoine (sous forme d'antimoniate de méglumine monohydraté) Apis mellifera Apocynum cannabinum Apomorphine (sous forme de chlorhydrate hémihydraté) Apramycine Apramycine (sous forme de sulfate) Aprotinine Aprotinine (solution concentrée) Arachide (huile d') hyperoxygénée Argent colloïdal pour usage externe Arginine Arginine (sous forme d'aspartate) Arginine (sous forme de chlorhydrate) Aristolochia Arnica Arnica (extrait fluide d') Arnica (teinture d') Artemisia abrotanum Articaïne (sous forme de chlorhydrate) Artichaut Artichaut (extrait sec d') Artichaut (poudre d') Artichaut (teinture d') Asparagine Asparagine (sous forme de monohydrate) Astémizole Aténolol Atipamézole (sous forme de chlorhydrate) Atropine Atropine (sous forme de sulfate monohydraté) Attapulgite activée Aurothiomalate de sodium Autolysat de poisson Avilamycine Azagly-nafaréline Azaméthifos Azapérone Azathioprine Azélastine (sous forme de chlorhydrate) Azithromycine Azorubine Bacampicilline (sous forme de chlorhydrate) Bacitracine Bacitracine (sous forme de sel de zinc) Baclofène Badiane Bambutérol (sous forme de chlorhydrate) Baquiloprime Barbital Bardane (extrait mou de) Baryum (sulfate de) Baume du Pérou Béclométasone (sous forme de dipropionate) Béclométasone (sous forme de dipropionate) monohydraté Belladone Bénazépril (sous forme de chlorhydrate) Bendiocarbe Bendrofluméthiazide Benfluorex (sous forme de chlorhydrate) Benpéridol Bensérazide (sous forme de chlorhydrate) Benzbromarone Benzéthonium (chlorure de) Benzétimide (sous forme de chlorhydrate) Benzocaïne Benzododécinium (sous forme de chlorure) Benzonaphtol Benzydamine (sous forme de chlorhydrate) Benzylidène acétone Benzylpénicilline (sous forme de bénéthamine) Benzylpénicilline (sous forme de benzathine tétrahydratée) Benzylpénicilline (sous forme de procaïne monohydratée) Benzylpénicilline (sous forme de sel de potassium) Benzylpénicilline (sous forme de sel de sodium) Bésilate d'atracurium Beta-acétyldigoxine Bétacarotène Bétadex Bétahistine (sous forme de dichlorhydrate) Bétahistine (sous forme de mésilate) Bétaïne Bétaïne (sous forme de chlorhydrate) Bétaméthasone Bétaméthasone (sous forme d'acétate) Bétaméthasone (sous forme de dipropionate) Bétaméthasone (sous forme de phosphate de disodium) Bétaméthasone (sous forme de valérate) Bétaxolol (sous forme de chlorhydrate) Bézafibrate Bicarbonate de potassium Bicarbonate
Load more

Recommended publications
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization II International Bureau (10) International Publication Number (43) International Publication Date WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 513/04 (2006.01) A61P 3/10 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/542 (2006.01) A61P 25/28 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/IB2014/058777 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 4 February 2014 (04.02.2014) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/765,283 15 February 2013 (15.02.2013) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, New York, New York 10017 (US).
    [Show full text]
  • Evaluation of the Efficacy of IQV04 for Weight Loss in Overweight and Obese Dogs
    Evaluation of the efficacy of IQV04 for weight loss in overweight and obese dogs. Annika Bieze 3514870 Supervisor: Dr. R.J. Corbee Abstract Introduction: Overweight and obesity are worldwide problems. Because of the higher risk of associated diseases, it is better to prevent and treat overweight and obesity. Beside weight loss programs, there are different medications and supplements available. After promising results from human health studies on the efficacy of Litramine, a similar product, named IQV04, is developed for dogs to support weight loss. The objective of this study was to evaluate the efficacy of IQV04 for weight loss in overweight and obese dogs. Materials and methods: Nineteen colony dogs were randomly divided in three groups, in this placebo controlled and double-blinded study. All dogs received once a day a standardised maintenance meal for their resting energy requirement (RER) with one of the three pills (IQV04 concentration A, IQV04 concentration B and placebo). Body weight and pelvic circumference were measured weekly. By start and end of the study, physical examination, body condition score, complete blood count, serum biochemical analysis and fecal examination was done. Results: Results suggested that there was a difference in body weight reduction between the three groups. The rate of weight loss in the placebo, IQV04 concentration A and IQV04 concentration B group were 2.45 ± 0.51, 2.85 ± 1.84 and 3.03 ± 1.26% body weight reduction per week, respectively. However, this difference did not reach significance. Also there was no significant difference found in pelvic circumference reduction per week. Conclusion: Further studies with larger patient pool are required to achieve more statistic power.
    [Show full text]
  • Small Animal Formulary 6Th Edition
    BSAVA Small Animal Formulary Ian Ramsey 6th edition Small Animal Formulary 6th edition Editor-in-Chief: Ian Ramsey BVSc PhD DSAM DipECVIM-CA FHEA MRCVS Small Animal Hospital, University of Glasgow, Bearsden Road, Bearsden, Glasgow G61 1QH Published by: British Small Animal Veterinary Association Woodrow House, 1 Telford Way, Waterwells Business Park, Quedgeley, Gloucester GL2 2AB A Company Limited by Guarantee in England. Registered Company No. 2837793. Registered as a Charity. Copyright © 2008 BSAVA First edition 1994 Second edition 1997 Third edition 1999 Reprinted with corrections 2000 Fourth edition 2002 Reprinted with corrections 2003 Fifth edition 2005 Reprinted with corrections 2007 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder. A catalogue record for this book is available from the British Library. ISBN 978 1 905319 11 4 The publishers and contributors cannot take responsibility for information provided on dosages and methods of application of drugs mentioned in this publication. Details of this kind must be verified by individual users from the appropriate literature. Printed by: HSW Print, Rhondda, Wales. ii BSAVA Small Animal Formulary 6th edition Other titles from BSAVA: Manual of Canine & Feline Abdominal Surgery Manual of Canine & Feline Anaesthesia and Analgesia Manual of Canine & Feline Behavioural Medicine Manual
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • WO 2013/150416 Al 10 October 2013 (10.10.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/150416 Al 10 October 2013 (10.10.2013) P O P C T (51) International Patent Classification: sachusetts 02460 (US). FUTATSUGI, Kentaro; 97 West C07D 471/04 (2006.01) A61K 31/519 (2006.01) Main Street, Unit 29, Niantic, Connecticut 06357 (US). C07D 473/32 (2006.01) A61K 31/52 (2006.01) HEPWORTH, David; 282 Sudbury Road, Concord, M as C07D 487/04 (2006.01) A61P 3/10 (2006.01) sachusetts 01742 (US). KUNG, Daniel W.; 289 Laurel- C07D 519/00 (2006.01) wood Drive, Salem, Connecticut 06420 (US). ORR, Suvi; 16 Seabreeze Road, Old Saybrook, Connecticut 06475 (21) International Application Number: (US). WANG, Jian; 164 White Street, Belmont, Mas PCT/IB20 13/052404 sachusetts 02478 (US). (22) International Filing Date: (74) Agents: KLEIMAN, Gabriel L. et al; Pfizer Inc., 235 26 March 2013 (26.03.2013) East 42nd Street, New York, NY 1001 7 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 61/621,144 6 April 2012 (06.04.2012) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, New York, New York 10017 (US).
    [Show full text]
  • Small Animal Obesity: Effective Control, Management and Care
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk SMALL ANIMAL OBESITY: EFFECTIVE CONTROL, MANAGEMENT AND CARE Author : Catherine F Le Bars Categories : Vets Date : February 23, 2009 Catherine F Le Bars explains how the battle of the bulge and the medical implications specific to certain species need a careful approach to both owner and pet OBESITY is one of the most common nutrition-related conditions in companion animals in the industrialised world, and has a proven association with the development of several disease conditions and reduced longevity. Since weight gain occurs when daily energy intake exceeds energy expenditure, the prevention of obesity requires strict attention to the animal’s nutrition throughout its life. Obesity treatment may be complicated by many factors, and successful management of the condition relies on rigorous owner compliance. Estimates from around the world put the incidence of obesity in dogs and cats at up to 40 per cent, and a number of risk factors have been implicated in its development. These include breed, age, gender, neutering, medication (anti-convulsants, glucocorticoids and contraceptives), lifestyle and exercise, co-existing disease (diabetes mellitus, hypothyroidism, hyperadrenocorticism) and diet. The regulation of food intake is dependent on a complex balance of long-term and shortterm signals to the brain, which are aimed at controlling the fat mass of the animal. When this balance is disrupted, the animal consumes energy above its requirements and gains weight. There are three recognised stages of weight gain: 1 / 10 • A “static ” pre-obesity stage, whereby energy intake is increased but bodyweight remains the same.
    [Show full text]
  • The Comparison of the Effect of Dietary Changes Or Dirlotapide
    THE COMPARISON OF THE EFFECT OF DIETARY CHANGES OR DIRLOTAPIDE TREATMENT ON CANINE OBESITY IN A SMALL ANIMAL VETERINARY PRACTICE A Report of a Senior Study by Anna Elizabeth McRee Major: Biology Maryville College Fall, 2009 Date Approved _____________, by ________________________ Faculty Supervisor Date Approved _____________, by ________________________ Editor ii ABSTRACT One of the greatest clinical challenges in contemporary veterinary medicine is canine obesity, which in the U.S. is increasing similar to trends observed in humans. Obesity impedes the overall wellness of canine patients; it is associated with shorter lifespan in domesticated dogs. The purposes of this study were to evaluate the incidence of obesity in one particular East Tennessee small animal veterinary practice and to examine the efficacy of two readily available treatment tools for this disease: pharmaceutical therapy with dirlotapide or dietary intervention through either caloric restriction or a high fiber diet. The incidence of obesity was examined by recording the body condition score (BCS) on a 1-9 scale for every dog that entered My Pets Animal Hospital for 2 consecutive months during the summer of 2009. Data for 594 dogs was collected in this manner and 4 treatment groups were also evaluated to examine the efficacy of treatment protocols. This study presents two major findings: (1) that 67 % of dogs at this particular veterinary clinic were overweight/obese (based on a BCS score of 6 or greater) and (2) that both dietary changes and pharmaceutical treatment were equally effective at promoting weight reduction in obese canines, as there was no significant difference in the percent weight loss per 30 days (p = 0.969).
    [Show full text]
  • Phytochemicals for Controlling Obesity-Related Cancers
    Crimson Publishers Review Article Wings to the Research Phytochemicals for Controlling Obesity-Related Cancers Madhumita Roy1*and Amitava Datta2 1Department of Environmental Carcinogenesis and Toxicology, Chittaranjan National Cancer Institute, 37, S. P. Mukherjee Road, Kolkata-700026, India 2Department of Computer Science and Software Engineering, University of Western Australia. 35 Stirling Highway, Perth, WA 6009, Australia ISSN: 2637-773X Abstract Obesity related diseases are on the rise worldwide and obesity is an economic burden on the public health system in most developed and developing countries. The control of obesity is a major challenge that is hard to solve using medication and surgical procedures as those often have serious side effects. Our focus in this article is to highlight the extensive research literature on use of plant-derived chemicals or phytochemicals for control of obesity and obesity related diseases with a particular focus on several types of cancer. We discuss the genes, proteins and pathways involved in obesity and its control, and discuss these genes and pathways. how current research has revealed the beneficial effects of plant-derived chemicals or phytochemicals on Keywords: Obesity; Phytochemicals; Cancer; Adiposity; BMI; Signalling pathways; Genes Introduction *Corresponding author: Madhumita Roy, Department of Environmental Obesity is the state of being overweight, a condition caused due to excessive rate of Carcinogenesis and Toxicology, accumulation and storage of fat in the body. Obesity not only affects appearance, but leads Chittaranjan National Cancer Institute, 37, to a number of health issues. The disparity in calorie consumption and calorie burning leads S. P. Mukherjee Road, Kolkata-700026, to energy imbalance, which is a lead cause of obesity.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • List Item Yarvitan : EPAR
    SCIENTIFIC DISCUSSION 1 SUMMARY OF THE DOSSIER Yarvitan, a 5 mg/ml, oral solution contains mitratapide as active substance. Mitratapide is a potent inhibitor of the microsomal triglyceride transfer protein (MTP). The benefits of Yarvitan are its ability to reduce bodyweight in adult dogs when given in accordance with the approved treatment schedule of 2 periods of 21 days with 14 days without treatment in between. The majority of overweight dogs are overweight from excess body fat. Several predisposing factors relate to the development of obesity in companion animals, including: advancing age, breed, neutering, excessive or inappropriate feeding and infrequent exercise or inactivity. The treatment with Yarvitan is given orally with food once daily. The most common side effects are vomiting, diarrhoea or softened stools. 2. QUALITY ASSESSMENT Composition authorised Yarvitan oral solution contains 5 mg/ml mitratapide as active substance. Conventional pharmaceutical excipients (flavouring agent, anti-oxidant and solvent) are used and full details are included in the SPC. Container Yarvitan is presented in amber glass bottles with polypropylene child resistant caps with a low density polyethylene (LDPE) liner fitted with an insert for an LDPE/polystyrene dosing pipette. The dosing pipette is supplied separately to the bottle and two separate dosinglonger pipettes sizes are available. A 4 ml pipette will be supplied with the 55 and 120 ml bottles and a 6 ml pipette with the 210 ml bottle. Three container volumes are proposed: 55 ml (in 60 ml nominal bottle) - 120 ml (in 125 ml nominal bottle) - 210 ml (in 230 ml nominal bottle). All packaging components are suitable for pharmaceutical use.
    [Show full text]